# SKYSCRAPER-02C (NCT04665856)

> Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: tiragolumab plus atezolizumab
- Indication: untreated extensive-stage small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04665856
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Small Cell Lung Carcinoma
- Interventions: Tiragolumab; Atezolizumab; Carboplatin; Etoposide; Tiragolumab Matching Placebo
- Enrollment: 123
- Primary outcome: Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)
- Primary outcome: Overall Survival (OS) in the PAS

## Indexed commentary on SKYSCRAPER-02C so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=skyscraper-02c-nct04665856